P

Parexel

End-to-end clinical trials and regulatory consulting

Vice President - Commercial Strategy

Full-Time
No salary listed
Expert
Bachelor's, Master's
Remote in USA+1 moreMore locations: Remote in Canada
Remote
Business & StrategyCorporate Strategy

About the job

Requirements
  • Exceptional interpersonal, verbal, and written communication and presentation skills that inspire confidence and drive engagement.
  • Advanced negotiation, influencing, and persuasion capabilities with the ability to shape strategy and drive stakeholder alignment.
  • Demonstrated leadership and ability to influence multiple stakeholders across functions to set strategy and oversee successful implementation.
  • Strong business acumen and strategic thinking with the ability to identify market opportunities and competitive positioning.
  • Executive presence with the ability to build trusted relationships and interface effectively with external clients and internal employees at all organizational levels.
  • Strong analytical, problem-solving, and decision-making skills combined with creativity and strategic insight.
  • Collaborative, inclusive, and proactive attitude with demonstrated ability to foster teamwork across diverse teams and drive achievement of goals.
  • Exceptional attention to detail and accuracy with strong organizational skills and ability to manage multiple priorities.
  • Willingness to travel as needed for the position.
  • 15+ years of successful track record in the contract research organization industry with extensive client management experience and background in senior sales and/or operational roles.
  • Extensive experience in development of commercial messaging including proposal writing, requests for information, sales and marketing materials, and bid pursuit content.
  • Proven experience leading and managing global cross-functional teams.
  • Proficiency with commercial and bid tools and software including Microsoft Office, Salesforce, and proposal or presentation automation platforms.
  • Superior understanding of commercial strategy messaging, selling with insight, and data-driven methodologies.
  • Strong knowledge of the contract research organization industry, the biopharma market, and the products and services that Parexel offers.
  • General understanding of medical terminology and International Council for Harmonisation Good Clinical Practice.
  • Strong communication, organization, and problem-solving skills
Responsibilities
  • Participate in bid triage discussions to evaluate incoming opportunities, assess strategic fit, and align pursuits with corporate objectives.
  • Conduct comprehensive market and competitive analysis to identify, qualify, and prioritize high-value opportunities that align with Parexel's capabilities and growth strategy.
  • Provide expert guidance and coaching to bid teams on high-profile requests for information and requests for proposal opportunities, ensuring competitive and compelling sales messaging that differentiates Parexel and drives successful outcomes.
  • Collaborate closely with sales teams, technical experts, and operational colleagues to understand client requirements, assess opportunity scope, and develop winning strategies.
  • Prepare bid teams for client presentations and interactions through constructive feedback and strategic positioning to maximize Parexel's competitive advantage.
  • Extract and disseminate lessons learned from wins and losses across the organization to continuously improve commercial effectiveness and bid pursuit outcomes.
  • Monitor industry trends, policy changes, regulatory developments, and emerging technologies that may impact Parexel's market positioning and competitive strategy.
  • Participate in bid pursuits and client engagements as needed to strengthen relationships and represent Parexel's strategic capabilities.
  • Represent Parexel at industry conferences and events to stay informed on market developments, engage with customers, and enhance Parexel's industry visibility.
  • Lead or participate in internal initiatives to optimize commercial hit rate and enhance bid pursuit effectiveness.
  • Collaborate with Sales Operations and business leaders on analysis of wins and losses, and development and dissemination of key commercial insights.
  • Participate in development of training materials and resources on commercial strategy and bid pursuit best practices
Desired Qualifications
  • Bachelor's degree in a scientific or business discipline.
  • Advanced degree in business, science, or related field.
  • Experience in pharmaceutical medicine or related therapeutic areas.
  • Demonstrated success in business development or new business pursuits.

About the company

P

Parexel

View
Website

Parexel provides end-to-end clinical development services for pharmaceutical, biotechnology, and medical device clients from Phase I to Phase IV. Its offerings include clinical trial management, regulatory consulting, and biostatistical analysis to support the design, execution, and analysis of clinical studies. The company operates as a CRO, partnering with sponsors to manage trials, ensure regulatory compliance, and generate robust data for drug development. What sets Parexel apart is its breadth of services across the trial lifecycle, emphasis on quality and reliability, and industry recognition, along with a focus on patient-centric approaches and leadership in gender partnership. The company’s goal is to help clients bring new therapies to market efficiently and safely by delivering high-quality, compliant trial outcomes and data that support regulatory submissions.

Company Size

10,001+

Company Stage

Acquired

Total Funding

$8.5B

Headquarters

Durham, North Carolina

Founded

1982

Get referred to Parexel

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 23, 2026 FSP overhaul expands higher-margin lifecycle services and flexible capacity.
  • June 2026 oncology and hematology launches showcase 250 hematology programs and 560 oncology studies.
  • Parexel won 2025 Scrip CRO and July 2026 Disability Index recognition, aiding employer brand.

What critics are saying

  • S&P kept Parexel’s outlook negative in December 2025 at about 6.5x leverage.
  • A California civil-rights jobs case filed August 26, 2026 adds legal and reputational drag.
  • Soft CRO demand and January 2026 restructuring cut 150 workers, squeezing morale and hiring.

What makes Parexel unique

  • ParexelAI and FSP Integrated Solutions unify AI, talent, and delivery across trials.
  • Parexel’s June 2026 Biotech Incubator links Raleigh scientists to clinical and regulatory experts.
  • Parexel spans 22,000 employees and 40+ years across Phase I-IV development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

5%

2 year growth

5%
Africa Daily Journal
Oct 14th, 2026
Parexel to spotlight Site Partnership, Innovation & industry-leading site performance at 2026 Society for Clinical Research Sites (SCRS) Global Site Solutions Summit(TM).

Parexel to spotlight Site Partnership, Innovation & industry-leading site performance at 2026 Society for Clinical Research Sites (SCRS) Global Site Solutions Summit(TM). Company brings its expertise in driving faster site activation and enrollment and better patient retention to panel discussions; continues commitment to helping sites navigate growing trial complexity Company also honors recipients of 2026 Parexel Emerging Site Scholarship, supporting and celebrating the next generation of research sites RALEIGH, N.C., Oct. 14, 2026 (GLOBE NEWSWIRE) - Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry, today announced it will lead discussions on site activation and engagement, recognize emerging sites and support initiatives designed to strengthen site partnerships at the 2026 Society for Clinical Research Sites (SCRS) Global Site Solutions Summit(TM) October 15-18 in Orlando, Fla. "Sites are essential partners in clinical trials, expanding access to research and helping bring new medicines to patients faster," said Rob Goodwin, Chief Operating Officer, Parexel. "As sites face growing complexity and operational pressures, Parexel works alongside them to develop targeted solutions that make their day-to-day management of the site easier, improve efficiency and ultimately strengthen study execution." Parexel will lead a workshop at the Site Partnership Symposium and present on two expert panels: * Site Partnership Symposium: "Building Resilient Site-CRO Partnerships: Working Together In The Era of Innovation" * Date and time: Thursday, October 15 from 8:30 a.m. - 9:30 a.m. ET * Context: In an increasingly competitive and evolving clinical research landscape, partnership between research sites and CROs is more important than ever. This interactive symposium will explore how sites can maximize their collaboration with CROs, building resilient, future-ready relationships that thrive amid technological advancement and industry transformation. * "From Feasibility to First Choice: What Sponsors Really Want" * Panelist: Shanna Nixon, Senior Director, Site Alliance, Parexel * Date and time: Saturday, October 17 from 1:30 p.m. - 2:30 p.m. ET * Context: Sponsors explain what drives site selection decisions beyond enrollment numbers and therapeutic experience. The session will explore what "study-ready" actually means and how to build trusted relationships that lead to increased study opportunities. * "Care By Design: Integrating Oncology & Clinical Trials Into Site Strategy" * Panelist: Mireille Carrillo, Senior Site Alliance Manager, Parexel * Date and time: Saturday, October 17 from 3:30 p.m. - 4:30 p.m. ET * Context: As clinical trials become pathways to care, sites must move beyond reactive feasibility toward earlier, more intentional decision-making. This session reframes site strategy by aligning patient identification, physician engagement and portfolio selection with modern care delivery. Complementing these thought leadership sessions, Parexel is proud to host a breakfast honoring the recipients of the 2026 Parexel Emerging Site Scholarship and sponsor the Site Appreciation Reception for the fourth consecutive year. During the Eagle Award Gala, Parexel will present the inaugural Next Up Award to early-career industry professionals who are creating meaningful change at the site level. "Parexel is deeply committed to supporting sites' success through programs like our Site Activation Center of Excellence, Emerging Site Scholarship Program and collaborative research forums," said Marta León Montagut, Senior Vice President, Site Activation Center of Excellence, Parexel. "Our global team of nearly 1,000 site activation professionals across 41 countries provides the expertise and support needed to accelerate trial startup and patient enrollment." Parexel's approach to site engagement is designed to strengthen site partnerships, deliver measurable performance improvements and support the next generation of research sites through targeted investments and development programs. This includes: Parexel Site Alliance Network: Alliance sites meet rigorous quality and performance standards and bring deep therapeutic expertise across oncology/hematology, rare disease, ophthalmology, neuroscience, immunology and infectious disease that helps accelerate study delivery. As one of the industry's largest site engagement networks, it is designed to strengthen collaboration and improve study execution. With more than 300 alliance sites and 16,000 investigators globally, the network has achieved: * 40% faster from activation to First Patient First Visit (FPFV) than non-alliance sites * Nearly 25% faster study start-up completion and contract cycle timelines * 48% higher patient enrollment per site, on average, than non-alliance sites Performance across clinical development: Across Phase II and III studies, Parexel consistently outperforms industry benchmarks: * 30% fewer non-enrolling sites * 30% more participants randomized per site per month * 41% lower dropout rates Parexel Emerging Site Scholarship Program: Now in its third year and expanding globally, the program helps strengthen the next generation of research sites. * Mentorship from experienced research site leaders * Dedicated support from Parexel site experts * One-year SCRS membership and complimentary registration to an SCRS Site Solutions Summit * Professional development and educational opportunities Joining Rob Goodwin, Marta León Montagut, Shanna Nixon and Mireille Carrillo at the Global Site Solutions Summit(TM) will be Leslie Ives, Senior Director, Patient and Site Engagement, along with additional members of Parexel's Global Site Activation team. Attendees can visit Booth 601 to meet the team and learn more about the company's approach to site engagement, activation and operational excellence. About SCRS The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 12,000 sites in 75+ countries, SCRS facilitates industry collaborations and conversations focused on site advocacy, education, mentorship and connection. About Parexel Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, its 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind - broadening access and making clinical research a care option for anyone, anywhere. Its proven track record spans 40+ years and drives Africa Daily Journal forward, advancing clinical research in healthcare's most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Its insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients - With Heart(R). Africa Daily Journal continue to earn recognition industrywide, including the 2025 Scrip Award for "Best Contract Research Organization - Full-Service Provider," the 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow Africa Daily Journal on LinkedIn, X, Facebook and Instagram. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa Daily Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

GlobeNewswire
Sep 23rd, 2026
Parexel transforms functional service provider (FSP) model to improve R&D productivity and enhance post-approval product lifecycle services for biopharmaceutical companies.

Parexel transforms functional service provider (FSP) model to improve R&D productivity and enhance post-approval product lifecycle services for biopharmaceutical companies. Integrated FSP model pairs specialist global talent with ParexelAI-enabled technology and operational expertise, enabling sponsors to better flex capacity as pipelines shift. RALEIGH, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE) - Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry, today announced the transformation of its functional service provider (FSP) services, to a new strategic business model, Parexel FSP Integrated Solutions. This technology-driven approach is designed to help sponsors extend capacity and capability, access specialized expertise and improve R&D productivity and enhance post-approval product lifecycle services as global development programs grow more complex. To lead this transformation, Parexel has appointed Sanjay Vyas as President, Integrated Solutions, Clinical Logistics & Managing Director India, a newly created role that will unify Parexel's FSP offerings across functions into a single, coordinated delivery model, giving customers new tech-enabled capabilities and a single point of accountability. FSP Integrated Solutions fully leverages ParexelAI(TM) to provide an enterprise capability partner that allows customers to more efficiently access expertise, technology and talent through custom solutions, configured to the scope and duration each program requires. "Biopharmaceutical companies are facing unprecedented pressure to improve R&D productivity and enhance post-approval product lifecycle activities while navigating increasingly complex development programs, especially as the industry moves away from headcount-based outsourcing," said Rob Goodwin, Chief Operating Officer, Parexel. "Customers need partners that take greater accountability for outcomes and can deliver the flexible capacity, functional expertise, AI-enabled technology and scale required to evolve alongside their business. Our integrated FSP model is helping sponsors build more agile operating models that improve execution and accelerate development." Parexel FSP Integrated Solutions enables customers to: * Build flexible global operating models aligned to long-term business objectives * Scale capacity up or down as pipeline demands change, with faster access to global infrastructure, local expertise and specialist talent * Apply ParexelAI capabilities to automate manual work, streamline workflows and increase speed and efficiency * Improve productivity through deeply integrated people, process and technology solutions * Access 8,000+ FSP resources and a full breadth of functional capabilities across clinical, data management, biometrics, regulatory, and safety "Customers are telling us they want fewer handoffs and clearer accountability, not simply more people," said Sanjay Vyas. "Bringing our technology-enabled solutions, functional teams and consulting capabilities together under one powerful model lets us stand up the right expertise faster, deploy it where programs need it most, and deliver on the outcomes sponsors actually care about. I look forward to driving this effort in close partnership with industry veteran and FSP expert Rob Goodwin along with our broader Parexel team to bring a more unified experience to the organizations we serve." Built on Parexel's global delivery experience and deep therapeutic expertise, FSP Integrated Solutions extends the company's ongoing investment in technology-driven integrated services - including its ParexelAI suite of AI capabilities - that reduce complexity for customers and accelerate the delivery of therapies to patients. About Parexel Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, its 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind - broadening access and making clinical research a care option for anyone, anywhere. Its proven track record spans 40+ years and drives PowerConnect forward, advancing clinical research in healthcare's most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Its insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients - With Heart(R). PowerConnect continue to earn recognition industrywide, including the 2025 Scrip Award for "Best Contract Research Organization - Full-Service Provider," the 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow PowerConnect on LinkedIn, X, Facebook and Instagram.

The PBC Group
Sep 23rd, 2026
AI beyond the hype: inside the Parexel workshop that put clinical AI on trial at COG: CRO Summit Europe 2026.

AI beyond the hype: inside the Parexel workshop that put clinical AI on trial at COG: CRO Summit Europe 2026. Every conference this year has an AI session. Most of them look the same: a keynote, some slides, applause. COG: CRO Summit Europe's did not. Opening to the soundtrack from the 1968 film 2001: A Space Odyssey, "Also Sprach Zarathustra" and closing with a black envelope, Parexel's Martine Folkertsma and Barry O'Mara turned 90 minutes of stage time into something closer to a live experiment, encouraging a room of clinical operations leaders to stop talking about AI in the abstract and start defending real, costed decisions in front of their peers. The premise was simple and a little uncomfortable: everybody has an AI strategy, but fewer have an AI answer. Rather than accept that as a talking point, the session closed the gap in real time. Tables were given roles - a Host, a Scribe, a Skeptic - and put through three rounds, each one sharper than the last, with live Slido outputs pulled back onto the big screen so the room could watch its own thinking take shape. Round one, "Reality Check", asked tables to name the AI myth they were most tired of hearing, and what they'd actually stop or start doing about it. Round two raised the temperature: a hypothetical €10 million from the board, one initiative only, no portfolio to hide behind. Round three turned the knife inward, asking each table to argue why its own idea would fail. Barry O'Mara then grounded the exercise with a keynote on what translating AI ambition into practical reality looks like day to day at Parexel, before the room was sent off with an AI Reality Check card - five questions to ask before greenlighting the next initiative - tucked inside the black envelope. Being the closing session of the conference is normally a tough slot to fill, however this one didn't. If anything, the energy built: tables stayed fully engaged through all three rounds, and the closing reaction was overwhelmingly positive, with attendees repeatedly commenting on how refreshingly real the content from Martine and Barry felt against the usual conference closing-slot filler. Round 1 - Reality Check Seven minutes to name the AI myth the room was most ready to let go of. Round 2 - The €10 Million Decision Five minutes, one hypothetical board budget, one bet only. No portfolio to hide behind. Round 3 - Be The Board Seven minutes turning the knife inward: each table had to argue why its own idea would fail. A final word of thanks to Martine and Barry, who turned what could have been 90 minutes of AI platitudes into something the room had to work for. Watching European CRO leaders debate, in real time, about where their own money should go is a far better signal than any slide, and it leaves me genuinely excited to see how the sector turns that appetite into action over the 12 months ahead. Looking Forward The next edition of COG: CRO Summit Europe will begin planning soon... don't miss out! When: September, 2027 Where: Amsterdam, The Netherlands How to get involved: Sponsorship & Exhibiting - Alexander O'Leary ([email protected])

Alabama Cultural Times
Jul 27th, 2026
Parexel recognized as a World's Top Disability Inclusive Business by the Disability Index(R) from disability:in.

Parexel recognized as a World's Top Disability Inclusive Business by the Disability Index(R) from disability:in. Reflecting company's commitment to advancing inclusion and accessibility across its global workforce and in its clinical trials. RALEIGH, N.C., July 27, 2026 (GLOBE NEWSWIRE) - Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry, today announced its recognition as a World's Top Disability Inclusive Business based on its high performance on the Disability Index(R), the leading global benchmark for disability inclusion in business. "We are proud to be recognized as a World's Top Disability Inclusive Business, an achievement that underscores our continued commitment to fostering a culture where every colleague feels valued, respected and supported," said Peyton Howell, Chief Executive Officer. "This commitment is also integral to how we operate and deliver for patients. Bringing together diverse experiences and perspectives helps us design more patient-focused clinical research and develop solutions that reduce barriers to trial access and participation. Ultimately, we believe this commitment and approach support our mission to accelerate the delivery of life-changing treatments to patients around the world." Parexel's recognition reflects a comprehensive, company-wide commitment to creating an environment where colleagues and patients - regardless of physical ability or other differences - can participate and thrive in clinical research. This includes: * Leadership commitment, with inclusion embedded into governance, strategy and executive engagement * Inclusive culture and community, supported by Parexel's core values and ParAbility, an executive sponsored Business Resource Group dedicated to advancing accessibility, inclusion and support for all colleagues and patients * Innovative clinical research solutions that lower barriers to clinical trial participation for people with disabilities and reflect diverse patient population needs * Fairness in hiring and professional development, with accessible recruitment, accommodations and continuous learning opportunities * Accessible environments, including ongoing efforts to ensure physical and digital accessibility across the workplace and foster a culture of trust where colleagues feel comfortable disclosing disabilities and seeking support when needed * Comprehensive support and benefits, designed to promote well-being and equitable access for all colleagues * Strategic supplier partnerships, advancing opportunities for disability-owned businesses across the value chain The Disability Index is trusted by over 70% of the Fortune 100 and nearly half of the Fortune 500 and provides companies with data-driven insights to assess performance, identify opportunities and drive continuous improvement over time. The Disability Index uses a structured, data-driven methodology that enables consistent benchmarking across companies and industries. Companies scoring at the highest proficiency levels earn recognition as World's Top Disability Inclusive Businesses, signaling leadership and progress to employees, customers and partners. About Parexel Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, its 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind - broadening access and making clinical research a care option for anyone, anywhere. Its proven track record spans 40+ years and drives Alabama Cultural Times forward, advancing clinical research in healthcare's most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Its insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients - With Heart(R). Alabama Cultural Times continue to earn recognition industrywide, including the 2025 Scrip Award for "Best Contract Research Organization - Full-Service Provider," the 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow Alabama Cultural Times on LinkedIn, X, Facebook and Instagram. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Alabama Cultural Times do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Africa Daily Journal
Jun 22nd, 2026
Parexel launches Parexel Biotech Incubator to connect early-stage innovation with clinical development expertise.

Parexel launches Parexel Biotech Incubator to connect early-stage innovation with clinical development expertise. Initiative creates new resource to support and accelerate early-stage therapeutics companies Parexel forms inaugural partnership with Durham-based Cape Fear BioCapital to connect incubator to a seed-stage venture partner RALEIGH, N.C., June 22, 2026 (GLOBE NEWSWIRE) - Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry, today announced the launch of the Parexel Biotech Incubator, a new initiative anchored at the company's North Hills Innovation District global headquarters in Raleigh that connects early-stage therapeutics companies with the clinical and regulatory expertise they need to advance their programs. The incubator launches alongside an inaugural partnership with Cape Fear BioCapital, a Durham-based seed-stage venture capital firm, and builds on Parexel's growing commitment to supporting early-stage innovation in collaboration with the venture community. The Parexel Biotech Incubator is designed to support emerging therapeutics companies at a stage when development strategy is still taking shape. Participating companies will have access to Parexel's clinical and regulatory expertise - including guidance on development planning, regulatory strategy and clinical trial design - alongside shared physical space that puts them in direct proximity to Parexel's Raleigh-based team and provides a collaborative home rather than resources and investment alone. "Reaching innovators at the earliest stages of their development journey, before clinical programs are formally structured, is where we can have the greatest impact. That is exactly what this initiative is designed to do," said Peyton Howell, Chief Executive Officer of Parexel. "The incubator reflects the evolution of our support for the biotech community, connecting seed-stage investment to clinical development expertise at the stage when it matters most. It builds on our broader commitment to investing in early-stage innovation alongside leading venture firms, and our inaugural partnership with Cape Fear BioCapital deepens our roots in one of the most dynamic life sciences ecosystems in the country." The incubator builds on Parexel's broader commitment to investing in and fostering early-stage innovation alongside leading venture capital firms. Parexel has established collaborative relationships with leading venture firms as part of its strategy to advance and accelerate the next generation of therapeutics companies. The partnership with Cape Fear BioCapital is designed to address a gap that early-stage therapeutics companies frequently face, where seed-stage investment and clinical development expertise rarely come together at the right time. Cape Fear BioCapital focuses on advancing companies from early discovery through IND-readiness, and the alliance creates a direct connection between its portfolio companies and Parexel's clinical and regulatory expertise at the stage when development decisions carry the most weight. "The Parexel Biotech Incubator represents the next stage in Parexel Biotech's evolution and extends our long-standing commitment to the biotech community," said Jim Anthony, Chief Commercial Officer and President, Parexel Biotech. "By bringing our clinical and regulatory expertise to emerging innovators earlier in their development journeys, we can help companies make smarter development decisions, build stronger plans and position promising programs for lasting progress." North Carolina ranks seventh in the United States for life sciences employment, with more than 103,000 workers across nearly 6,700 establishments statewide. Anchored by Research Triangle Park, one of the world's largest research parks, the state is also home to leading research institutions including Duke University, the University of North Carolina at Chapel Hill and NC State University. Cape Fear BioCapital's deep ties to all three institutions reinforce the regional research pipeline helping shape North Carolina's next generation of therapeutics companies. "North Carolina has the scientific substrate, talent, and entrepreneurial ambition to build on our strong base of therapeutics innovation," said Dave Ousterout, General Partner at Cape Fear BioCapital. "Working together with Parexel, we are dedicated to supporting emerging companies and connecting them with development expertise at a stage when strategic guidance can make a meaningful difference. Our partnership reflects a shared commitment to strengthening the support and capital available to innovators across the state." Since establishing its Durham location in 2014, Parexel has continued to invest in North Carolina, expanding its presence in 2019 and opening its global headquarters in Raleigh's North Hills Innovation District in 2025. Launched in 2019, Parexel Biotech is the company's dedicated business unit serving emerging biopharmaceutical innovators and reflects Parexel's continued focus on supporting biotech companies as they navigate key development milestones. About the Parexel Biotech Incubator The Parexel Biotech Incubator gives early-stage companies direct access to Parexel's clinical and regulatory expertise, reflecting Parexel's commitment to engaging biotech innovators earlier and building relationships that support future development needs. It is anchored at Parexel's North Hills Innovation District global headquarters in Raleigh, supporting emerging therapeutics companies wherever they are based. About Cape Fear BioCapital Cape Fear BioCapital is a seed-stage venture capital firm dedicated to investing in and building early-stage therapeutics companies in North Carolina. Founded in 2024 by Ed Field, Jimmy Melton and Dave Ousterout, the firm works to advance portfolio companies from early discovery through IND-readiness, filling a critical gap in the state's early-stage life sciences funding landscape. Cape Fear BioCapital is anchored by Moore Strategic Ventures and maintains deep ties to Duke University, the University of North Carolina at Chapel Hill and NC State University. For more information, visit capefearbiocap.com. About Parexel Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, its 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind - broadening access and making clinical research a care option for anyone, anywhere. Its proven track record spans 40+ years and drives Africa Daily Journal forward, advancing clinical research in healthcare's most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Its insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients - With Heart(R). Africa Daily Journal continue to earn recognition industrywide, including the 2025 Scrip Award for "Best Contract Research Organization - Full-Service Provider," the 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow Africa Daily Journal on LinkedIn, X, Facebook and Instagram. Heather Zoumas-Lubeski +1 (984) 218-5539 [email protected] Danaka Williams +1 (984) 298-4207 [email protected] Parexel launches Parexel Biotech Incubator. Initiative creates new resource to support and accelerate early-stage therapeutics companies. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa Daily Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.